Best Low Price Stocks For 2019

By Ben Reynolds

Bank of Nova Scotia (NYSE:BNS) is the third-largest Canadian bank ranked by market cap.

Bank of Nova Scotia’s market cap is $64 billion The Toronto-Dominion Bank’s market cap is $83 billion Royal Bank of Canada’s market cap is $94 billion

Bank of Nova Scotia’s financial metrics should immediately stand out for value-focused dividend investors. The company has a high dividend yield of 4.1% and a low price-to-earnings ratio of 12.3. This helps the company to rank highly using The 8 Rules of Dividend Investing.

Bank of Nova Scotia released its 3rd quarter results on August 30. This article covers those results in detail.

Brief Overview

Bank of Nova Scotia operates in 4 segments:

Canadian Banking International Banking Global Banking & Markets Other

The Canadian Banking segment is the company’s largest. It generated $930 million in net profit in the company’s most recent quarter. The Canadian Banking segment provides Canada with retail, small business, commercial banking, and wealth management services. The segment has more than 10 million customers and 1,000 branches across Canada.

Best Low Price Stocks For 2019: Grupo Aval Acciones y Valores S.A.(AVAL)

Advisors’ Opinion:

  • [By Logan Wallace]

    Get a free copy of the Zacks research report on Grupo Aval Acciones y Valores (AVAL)

    For more information about research offerings from Zacks Investment Research, visit

Best Low Price Stocks For 2019: Cadiz, Inc.(CDZI)

Advisors’ Opinion:

  • [By Joseph Griffin]

    Cadiz (NASDAQ: CDZI) is one of 15 publicly-traded companies in the “Water supply” industry, but how does it contrast to its rivals? We will compare Cadiz to similar companies based on the strength of its valuation, profitability, institutional ownership, analyst recommendations, earnings, risk and dividends.

Best Low Price Stocks For 2019: Wausau Paper Corp.(WPP)

Advisors’ Opinion:

  • [By Lisa Levin] Gainers
    Bio-Path Holdings, Inc. (NASDAQ: BPTH) shares rose 29.5 percent to $2.15 in pre-market trading after reporting pre-clinical data demonstrating potential of Prexigebersen presented at the annual American Association for Cancer Research meeting in Chicago.
    Sientra, Inc. (NASDAQ: SIEN) rose 16.7 percent to $12.90 in pre-market trading following the announcement of FDA approval for PMA supplement.
    Aqua Metals, Inc. (NASDAQ: AQMS) rose 13.5 percent to $2.95 in pre-market trading after climbing 14.04 percent on Wednesday.
    Harmony Gold Mining Company Limited (NYSE: HMY) rose 5.6 percent to $2.09 in pre-market trading.
    Alcoa Corporation (NYSE: AA) shares rose 5 percent to $62.32 in pre-market trading after the company reported better-than-expected earnings for its first quarter and raised its FY18 adjusted EBITDA outlook.
    Gold Fields Limited (ADR) (NYSE: GFI) shares rose 4.9 percent to $4.11 in pre-market trading after gaining 1.03 percent on Wednesday.
    ABB Ltd (NYSE: ABB) shares rose 4.3 percent to $24.47 in pre-market trading after reporting Q1 results.
    WPP plc (NYSE: WPP) rose 4.2 percent to $82.99 in pre-market trading.
    American Express Company (NYSE: AXP) rose 4 percent to $98.95 in pre-market trading after the company reported stronger-than-expected profit for its first quarter.
    HSBC Holdings plc (NYSE: HSEA) rose 3.4 percent to $27.30 in pre-market trading.
    Shire plc (NASDAQ: SHPG) rose 3.4 percent to $167.95 in pre-market trading. Takada offered to buy Shire at £46.50 per share, Reuters reported.
    Vipshop Holdings Limited (NYSE: VIPS) rose 3.1 percent to $16.43 in pre-market trading.
    iRobot Corporation (NASDAQ: IRBT) shares rose 3 percent to $63.66 in the pre-market trading session.

    Find out what's going on in today's market and bring any questions you have to Benzinga's PreMarket Prep.

  • [By ]

    Embattled WPP Group (WPP) CEO Martin Sorrell, no stranger to business news channels and fat annual compensation checks, has quit as CEO. Below is a statement from Sorrell obtained by TheStreet.

Best Low Price Stocks For 2019: GlaxoSmithKline PLC(GSK)

Advisors’ Opinion:


    Up first on our list of potentially toxic trades is $98 billion healthcare stock GlaxoSmithKline plc (GSK) . GSK has actually been an attractive name to own lately. Shares are up about 10.6% since bottoming back in December, besting the S&P over that timeframe. But if you own GlaxoSmithKline, now’s the time to start thinking about taking some of those recent gains off the table — shares are looking “toppy” this spring.


    Two of our top holdings, GlaxoSmithKline (GSK) and Merck (MRK) have seen substantial improvement in earnings as new drugs start to build market share. Glaxo and Merck offer dividend yields of 4.71% and 3.08%, respectively.

  • [By Shane Hupp]

    GlaxoSmithKline (NYSE:GSK) was downgraded by equities research analysts at ValuEngine from a “hold” rating to a “sell” rating in a research note issued on Friday.

  • [By Sean Williams]

    Shares of Innoviva (NASDAQ:INVA), a biotechnology royalty company that develops respiratory therapeutics and is perhaps best known as GlaxoSmithKline’s (NYSE:GSK) development partner for its multiple next-generation COPD and asthma products, fell as much as 11% on Thursday. The reason behind Innoviva’s bad day can be traced to a proxy battle with activist hedge fund Sarissa Capital Management over seats on its board.

  • [By Sean Williams]

    Third, in late March, Mylan announced that the Food and Drug Administration had rejected its application to market a generic version of GlaxoSmithKline’s (NYSE:GSK) blockbuster asthma and COPD inhalable drug, Advair. GlaxoSmithKline’s Advair lost patent protection more than six years ago, but only within the past couple of years did the FDA lay out a course for generic drug producers to follow in order to get a generic version of the drug approved. Meanwhile, Glaxo still enjoys blockbuster sales of Advair as generic versions of the drug have yet to hit the market.


    Donald Trump understands how regulation harms both businesses and consumers, discouraging innovation and raising costs. In a recent news conference, he pledged to “cut regulations by 75%, maybe more.”  This is good news indeed for drug companies like GlaxoSmithKline (GSK).

Best Low Price Stocks For 2019: DBV Technologies S.A.(DBVT)

Advisors’ Opinion:

  • [By Lisa Levin]


    DBV Technologies SA – ADR (NASDAQ: DBVT) shares tumbled 50.6 percent to $23.73 after the company disclosed that its peanut allergy trial failed to meet primary endpoint.
    Connecture Inc (NASDAQ: CNXR) shares declined 40.8 percent to $0.290. Connecture reported that it will voluntarily delist from the NASDAQ for OTCQX Market.
    Walter Investment Management Corp (NYSE: WAC) slipped 19.2 percent to $0.410. On Friday, Walter Investment Management disclosed that it has reached an agreement with term lenders and senior noteholders on financial restructuring.
    Eldorado Gold Corp (USA) (NYSE: EGO) shares dropped 15.9 percent to $1.83. Eldorado Gold lowered its production guidance for its Kisladag operation.
    Seanergy Maritime Holdings Corp. (NASDAQ: SHIP) shares fell 15.4 percent to $1.04.
    Future Fintech Group Inc (NASDAQ: FTFT) dropped 13.6 percent to $1.53. Future FinTech reported filing of proxy statement, including proposal for corporate restructuring.
    Concordia International Corp (NASDAQ: CXRX) shares fell 12.3 percent to $0.500 after dipping 38.71 percent on Friday.
    Aemetis Inc (NASDAQ: AMTX) shares declined 11.3 percent to $0.550
    OncoSec Medical Inc (NASDAQ: ONCS) dipped 10.5 percent to $1.12. OncoSec reported a $7.1 million registered direct at-the-market offering at a price of $1.34375 per share.
    Evoke Pharma Inc (NASDAQ: EVOK) shares fell 10.35 percent to $3.08 after the company disclosed 'positive' topline results from comparative exposure pharmacokinetic study for Gimoti.
    Eiger Biopharmaceuticals Inc (NASDAQ: EIGR) shares dropped 9.4 percent to $11.60 as the company disclosed Phase 2 interim 24-week data with pegylated interferon lambda in Hepatitis Delta Virus infection at the American Association for the Study of Liver Diseases Meeting.
    Viking Therapeutics Inc (NASDAQ: VKTX) shares slipped 6.6 percent to $2.80. Viking Therapeutics presented results from proof-of-concept study of VK0214 in in vivo

  • [By Paul Ausick]

    DBV Technologies SA (NASDAQ: DBVT) dropped about 53.5% Monday to post a new 52-week low of $22.33 after closing at $48.07 on Friday. The stock’s 52-week high is $50.57. Volume of around 12 million was about 60 times the daily average. The French drug maker’s peanut allergy treatment failed a phase 3 study.

  • [By Lisa Levin]

    DBV Technologies SA – ADR (NASDAQ: DBVT) shares dropped 46 percent to $26.11 after the company disclosed that its peanut allergy trial failed to meet primary endpoint.

  • [By Monica Gerson]

    DBV Technologies SA ADR (NASDAQ: DBVT) is expected to post a quarterly loss at $0.60 per share.

    Northern Technologies International Corp (NASDAQ: NTIC) is projected to post its quarterly earnings.

Best Low Price Stocks For 2019: Bavarian Nordic A/S (BVNKF)

Advisors’ Opinion:


    Leuven, Belgium-based Tigenix (OTC:TGXSF) filed to go public in the U.S. in late 2015, only to become entangled with Bavarian Nordic (OTC:BVNKF) and Basilea Pharmaceutica (OTC:BPMUF) as the European drugmakers pulled back from NASDAQ. Tigenix subsequently increased its bank account following a 23.75 million placement in Belgium, and added an additional 25 million via a relationship with Takeda, before coming back to Wall Street in October 2016 with a revamped slate of underwriters.

Leave a Reply

Your email address will not be published. Required fields are marked *